Lonza invests US$927 million (CHF850 million) to construct two next-generation mammalian manufacturing facilities. The new state-of-the-art mammalian facilities will be located in Visp (CH) and Portsmouth (US).
Expansion in Visp (CH):
The new state-of-the-art facility designed with latest manufacturing technology is supposed to expand the capacity by six 20,000L bioreactors to meet the large-scale commercial production of biologics. It covers an area of 27,500 m2.
The facility with an investment of US$711 million (CHF650 million) will increase large-scale biologics manufacturing capacity.
The state-of-the-art with high throughput facility features perfusion capabilities and also supports the growth of high titer processes and accommodates the next generation of mammalian biologics.
The new facility is anticipated to open more than 300 new jobs and expected to be completed in 2024.
Expansion in Portsmouth (US):
The next-generation facility will expand the capacity up to eight 2,000L single-use bioreactors in support of the late-phase clinical and commercial development and manufacturing.
The facility with an investment of US$219 million (CHF 200 million) will cover an area of 3,000m2.The new facility will complement the current single-use network at Lonza sites in Hayward (US), Slough (UK), Tuas (SG) and Visp (CH).
The manufacturing facility is expected to be completed in 2023 and create 250 new positions.
|Budget||US$927 million (CHF850 million)|